Profile

Flexion Therapeutics is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on developing and commercializing a sustained release version of triamcinolone acetonide that is intended to be injected into the joint to treat osteoarthritis. It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.